diseases of upper digestive tract
Conditions
Interventions
Case series:Esomeprazole 20mg bid or Rabeprazole 20mg bid + bismuth 220mg bid + Amoxicillin 1g bid + tetracycline 750mg bid + furaxone 100mg bid, 14 days
Sponsors
Daping Hospital, the Third Military Medical University, Chongqing, China
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years old, male or female; 2. Outpatients with comfortable symptom like abdominal pain or bloating or sour regurgitation or belching or nausea or nausea or heartburn or pectoralgia or melena and so on; 3. 13C breath test positive; 4. All subject underwent upper endoscopy with gastric biopsy for culture and susceptibility testing before positive bacterial culture; 5. primary treatment with the eradication rigime on this study and the Helicobacter pylori status become negative; 6. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Using antibiotics, bismuth, probiotics, H2 receptor antagonists, PPI and drugs metaboliced through the cytochrome P450 2C19 Within four weeks before treatment; 2. Pregnant or lactating women; 3. Patients are also taking non-steroidal anti-inflammatory drugs, adrenocorticotro or alcohol or the presence of other study evaluated the impact of this serious disease such as severe liver disease, heart disease, kidney disease, cancer and other diseases; 4. used in this study for patients with drug allergy; 5. gastrectomy patients asia; 6. Participated in studies of other drugs before using this study medication within three months; 7. Other factors that were difficult to complete the follow-up or affecting compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| the reason of helicobacter pylori recurrence after treatment:recrudescence or reinfection or antibiotic resistance or hybrid strains infection;adverse event; | — |
Countries
China
Contacts
Public ContactChunhui Lan
Outcome results
None listed